Alexander Hovard Sparre-Ulrich

Title: Alexander Hovard Sparre-Ulrich: Innovator in Peptide Analogues

Introduction

Alexander Hovard Sparre-Ulrich is a notable inventor based in Copenhagen, Denmark. He has made significant contributions to the field of peptide analogues, particularly in the context of glucose-dependent insulinotropic peptides. His work has implications for treating various metabolic disorders.

Latest Patents

Sparre-Ulrich holds 2 patents that focus on innovative peptide analogues. His latest patents include "Long-acting GIP peptide analogues," which disclose glucose-dependent insulinotropic peptide (GIP)-derived peptide analogues GIPS-30 and GIP3-30. These analogues act as antagonists of the GIP receptor and incorporate at least one fatty acid molecule to enhance their half-life while preserving their antagonistic properties. Another significant patent is "GIP peptide analogues," which provides GIP-derived peptide analogues, such as GIP(3-30), for use as antagonists of the GIP receptor. These analogues are aimed at treating disorders like obesity, diabetes mellitus, and insulin resistance.

Career Highlights

Sparre-Ulrich is affiliated with the University of Copenhagen, where he conducts his research and development in peptide analogues. His work has garnered attention for its potential to address critical health issues related to metabolic disorders.

Collaborations

He collaborates with esteemed colleagues, including Mette Marie Rosenkilde and Jens Juul Holst, who contribute to the research and development of his innovative peptide analogues.

Conclusion

Alexander Hovard Sparre-Ulrich is a prominent figure in the field of peptide research, with a focus on developing novel treatments for metabolic disorders. His contributions through patents and collaborations highlight the importance of innovation in healthcare.